PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

Abstract

Background and purpose: To compare and characterize metabolic features of high-and low-grade glioma tumors using 68 Ga-PSMA-617 and 18 F-FDG positron emission tomography/computed tomography (PET/CT).Methods: Thirty patients who underwent both 68 Ga-PSMA-617 and 18 F-FDG PET/CT over 2 consecutive days and then underwent surgical treatment were retrospectively identified. All tumors were diagnosed histologically. This report includes 16 high-grade glioma (HGG) and 14 low-grade glioma (LGG) tumors. Standard uptake value (SUV) and target to nontarget (T/NT) were quantitatively investigated through the entire tumor region. Statistical analyses were performed using area under the curve (AUC) and comparison of two means.

Role of Peptides in Diagnostics

“…In this study, the patients (n = 30) underwent both 68 Ga-PSMA-617 and 18 F-FDG PET scans over two consecutive days and then surgical treatment was performed. This study revealed that the 68 Ga-PSMA-617 PET scan is superior to the 18 F-FDG PET scan in differentiating HGG and LGG [82].…”

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis

“…Overall, 209 records were identified and screened through the comprehensive literature search described above. Taking into account predefined eligibility criteria, these 209 records were assessed for eligibility and 201 records were excluded (178 as not in the field of interest, 6 as reviews, editorials, or letters, and 17 as case reports); 8 remaining articles were judged as eligible for inclusion in the systematic review (qualitative synthesis) after full-text assessment [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. No additional studies were eligible for inclusion after screening the references of these articles.…”

“…No additional studies were eligible for inclusion after screening the references of these articles. Six out of eight articles were included in the meta-analysis (quantitative synthesis) [ 20 , 21 , 22 , 23 , 25 , 26 ]; two studies included in the systematic review were excluded from the meta-analysis [ 24 , 27 ] due to possible partial patient data overlap with other studies of the same research group. Figure 1 summarizes the study selection process.…”

“…Diagnostic accuracy data of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HGG patients for each study are listed in Table 4 . Overall, the index test has demonstrated an excellent diagnostic performance in detecting HGG in all studies included in the systematic review, both on a per patient- and on a per lesion-based analysis and in different clinical settings (at initial diagnosis and in the suspicious recurrence after treatment) [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. Moreover, PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals was very useful in detecting multifocal disease in HGG patients [ 20 , 21 , 23 ].…”

“…Regarding toxicity and safety, the injection of PSMA-targeting radiopharmaceuticals was well tolerated, without any adverse event recorded [ 20 , 24 ]. The image quality of PET with PSMA-targeting radiopharmaceuticals was judged adequate [ 22 ] and interpretation of the images was very easy due to the absence of physiological radiopharmaceutical uptake in the normal brain parenchyma, without ambiguity in deciding whether the scan was positive or negative [ 26 ]. When reported, interobserver concordance for abnormal sites of radiopharmaceutical uptake at PSMA-targeted PET imaging was excellent [ 21 , 26 ].…”